Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Oct 17;2007(4):CD003421.
doi: 10.1002/14651858.CD003421.pub4.

Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients

I R Shilliday  1 , M Sherif
Affiliations
Meta-Analysis

Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients

I R Shilliday et al. Cochrane Database Syst Rev. .

Abstract

Background: The incidence of delayed graft function in cadaveric grafts has increased over the last few years due in part to the large demand for cadaveric kidneys necessitating the use of kidneys from marginal donors. Calcium channel blockers have the potential to reduce the incidence of post-transplant acute tubular necrosis (ATN) if given in the peri-operative period. However, there is controversy surrounding their use in this situation with no consensus as to their efficacy.

Objectives: To evaluate the benefits and harms of using calcium channel blockers in the peri-transplant period in patients at risk of ATN following cadaveric kidney transplantation.

Search strategy: We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library) MEDLINE (from 1966) and EMBASE (from 1980). The Trials Search Coordinator was contacted to develop the search strategy. Date of last search: January 2007

Selection criteria: Randomised controlled trials comparing calcium channel blockers given in the peri-transplant period with controls were included. Quasi-randomised trials were excluded.

Data collection and analysis: Data was extracted and quality assessed independently by two reviewers, with differences resolved by discussion. Dichotomous outcomes are reported as relative risk (RR) and measurements on continuous scales are reported as mean differences (WMD) with 95% confidence intervals (CI).

Main results: Thirteen trials (724 participants) were suitable for inclusion. Treatment with calcium channel blockers in the peri-transplant period was associated with a significant decrease in the incidence of post-transplant ATN (RR 0.62, 95% CI 0.46 to 0.85) and delayed graft function (RR 0.55, 95% CI 0.42 to 0.73). There was no difference between control and treatment groups in graft loss, mortality, requirement for haemodialysis. There was insufficient information to comment on adverse events.

Authors' conclusions: These results suggest that calcium channel blockers given in the peri-operative period may reduce the incidence of ATN post-transplantation. The result should be treated with caution due to the heterogeneity of the trials which made comparison of studies and pooling of data difficult.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1.1
1.1. Analysis
Comparison 1 Calcium channel blockers versus placebo/no treatment, Outcome 1 Graft loss.
1.2
1.2. Analysis
Comparison 1 Calcium channel blockers versus placebo/no treatment, Outcome 2 Mortality.
1.3
1.3. Analysis
Comparison 1 Calcium channel blockers versus placebo/no treatment, Outcome 3 Acute tubular necrosis post‐transplant.
1.4
1.4. Analysis
Comparison 1 Calcium channel blockers versus placebo/no treatment, Outcome 4 GFR/creatinine clearance.
1.5
1.5. Analysis
Comparison 1 Calcium channel blockers versus placebo/no treatment, Outcome 5 Serum creatinine umol/L.
1.6
1.6. Analysis
Comparison 1 Calcium channel blockers versus placebo/no treatment, Outcome 6 Delayed graft function.
See this image and copyright information in PMC

Update of

Comment in

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Dawidson 1991 {published data only}
    1. Dawidson I, Rooth P, Lu C, Sagalowsky A, Diller K, Palmer B, et al. Verapamil improves the outcome after cadaver renal transplantation. Journal of the American Society of Nephrology 1991;2(5):983‐90. [MEDLINE: ] - PubMed
Frei 1987 {published data only}
    1. Frei U, Margreiter R, Harms A, Bosmuller C, Neumann KH, Viebahn R, et al. Preoperative graft reperfusion with a calcium antagonist improves initial function: preliminary results of a prospective randomized trial in 110 kidney recipients. Transplantation Proceedings 1987;19(5):3539‐41. [MEDLINE: ] - PubMed
Harper 1997 {published data only}
    1. Harper SJ, Moorhouse J, Veitch PS, Bell PR, Horsburgh T, Walls J, et al. Improved immediate graft function with nifedipine in cyclosporine‐treated renal allograft recipients‐‐a randomized prospective study. Transplantation 1992;54(4):742‐3. [MEDLINE: ] - PubMed
    1. Harper SJ, Moorhouse J, Walls J, Veitch S, Bell PR, Donnelly J, et al. Protective effects of nifedipine in immediate and 6‐month graft function in cyclosporin A treated renal allograft recipients [abstract]. Nephrology Dialysis Transplantation 1991;6(11):904. [CENTRAL: CN‐00260679]
Kuypers 2004 {published data only}
    1. Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y. Calcium channel blockade and preservation of renal graft function in cyclosporine‐treated recipients: a prospective randomized placebo‐controlled 2‐year study. Transplantation 2004;78(8):1204‐11. [MEDLINE: ] - PubMed
    1. Kuypers DR, Neumayer HH, Fritsche L, Budde K, Vanrenterghem Y. Calcium channel blockade and prevention of renal graft function deterioration in cyclosporine treated recipients: a multi‐centre prospective, randomised , placebo controlled, 2 year study [abstract]. American Journal of Transplantation 2004;4(Suppl 8):432. [CENTRAL: CN‐00509299] - PubMed
Ladefoged 1994 {published data only}
    1. Ladefoged SD, Pederson E, Hammer M, Rasmussen KC, Hansen FM, Andersen CB. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple‐drug immunosuppression: a randomized, double‐blind, placebo‐controlled study. Nephrology Dialysis Transplantation 1994;9(5):543‐7. [MEDLINE: ] - PubMed
Lustig 1996 {published data only}
    1. Lustig S, Shmueli D, Boner G, Bar‐Nathan N, Nakache R, Yussim A, et al. Gallopamil reduces the post‐transplantation acute tubular necrosis in kidneys from aged donors. Israel Journal of Medical Sciences 1996;32(12):1249‐51. [MEDLINE: ] - PubMed
Morales 1990 {published data only}
    1. Morales JM, Andres A, Alvarez C, Prieto C, Ortuno B, Ortuno T, et al. Calcium channel blockers and early cyclosporine nephrotoxicity after renal transplantation: a prospective randomized study. Transplantation Proceedings 1990;22(4):1733‐5. [MEDLINE: ] - PubMed
Neumayer 1989 {published data only}
    1. Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function by diltiazem and iloprost. Transplantation Proceedings 1989;21(1):1221‐4. [MEDLINE: ] - PubMed
    1. Neumayer HH, Wagner K. Prevention of delayed graft function in cadaver kidney transplants by diltiazem: outcome of two prospective, randomized clinical trials. Journal of Cardiovascular Pharmacology 1987;10 Suppl 10:S170‐7. [MEDLINE: ] - PubMed
    1. Wagner K, Albrecht S, Neumayer HH. Prevention of posttransplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. American Journal of Nephrology 1987;7(4):287‐91. [MEDLINE: ] - PubMed
    1. Wagner K, Neumayer HH. Influence of the calcium antagonist diltiazem on delayed graft function in cadaveric kidney transplantation: results of a 6‐month follow‐up. Transplantation Proceedings 1987;19(1 Pt 2):1353‐7. [MEDLINE: ] - PubMed
Neumayer 1992a {published data only}
    1. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney International ‐ Supplement 1992;36:87‐93. [MEDLINE: ] - PubMed
    1. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of diltiazem and the prostazycline analogue iloprost in human renal transplantation. Renal Failure 1992;14(3):289‐96. [MEDLINE: ] - PubMed
Neumayer 1992b {published data only}
    1. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney International ‐ Supplement 1992;36:87‐93. [MEDLINE: ] - PubMed
    1. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of diltiazem and the prostazycline analogue iloprost in human renal transplantation. Renal Failure 1992;14(3):289‐96. [MEDLINE: ] - PubMed
Oppenheimer 1992 {published data only}
    1. Alcaraz A, Oppenheimer F, Talbot‐Wright R, Fernandez‐Cruz L, Manalich M, Garcia‐Pages E, et al. Effect of diltiazem in the prevention of acute tubular necrosis, acute rejection, and cyclosporine levels. Transplantation Proceedings 1991;23(5):2383‐4. [MEDLINE: ] - PubMed
    1. Oppenheimer F, Alcaraz A, Manalich M, Ricart MJ, Vilardell J, Campistol JM, et al. Influence of the calcium blocker diltiazem on the prevention of acute renal failure after renal transplantation. Transplantation Proceedings 1992;24(1):50‐1. [MEDLINE: ] - PubMed
Tenschert 1991 {published data only}
    1. Tenschert W, Harfmann P, Meyer‐Moldenhauer WH, Arndt R, Klosterhalfen H. Kidney protective effect of diltiazem after renal transplantation with long cold ischaemia time and triple‐drug immunosuppression. Transplantation Proceedings 1991;23(1 Pt 2):1334‐5. [MEDLINE: ] - PubMed
Wilkie 1994 {published data only}
    1. Wilkie ME, Beer JC, Evans S, Lord RH, Raferty M, Marsh FP. Prospective trial of oral nifedipine on early renal allograft function [abstract]. Nephrology Dialysis Transplantaion. 1993; Vol. 8:1053‐4. [CENTRAL: CN‐00260901] - PubMed
    1. Wilkie ME, Beer JC, Evans SJ, Raftery MJ, Lord RH, Moore R, et al. A double‐blind, randomized, placebo‐controlled study of nifedipine on early renal allograft function. Nephrology Dialysis Transplantation 1994;9(7):800‐4. [MEDLINE: ] - PubMed

References to studies excluded from this review

Aros 2005 {published data only}
    1. Aros CA, Schneider HO, Flores CA, Ardiles LG, Alruiz PA, Jerez V, et al. Correlation between C2 and AUC(0‐4) in renal transplant patients treated with diltiazem. Transplantation Proceedings 2005;37(3):1580‐2. [MEDLINE: ] - PubMed
Barenbrock 1995 {published data only}
    1. Barenbrock M, Breuer J, Schroder K, Wagner K, Neumayer HH, Rahn KH. A study of the nehroprotective effect of nitrendipine after renal transplantation [abstract]. XIIIth International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:387. [CENTRAL: CN‐00509083]
Berg 1991 {published data only}
    1. Berg KJ, Holdaas H, Endresen L, Fauchald P, Hartmaan A, Pran T, et al. Effects of isradipine on renal function in cyclosporin‐treated renal transplanted patients. Nephrology Dialysis Transplantation 1991;6(10):725‐30. [MEDLINE: ] - PubMed
Calo 2002 {published data only}
    1. Calo L, Giacon B, Davis PA, Pagnin E, Piccin A, Riegler P, et al. Oxidative stress and TGFbeta in kidney‐transplanted patients with cyclosporin‐induced hypertension. Effect of carvedilol and nifedipine. Clinical Nephrology 2002;58(2):103‐10. [MEDLINE: ; CN‐00409977] - PubMed
Chanard 2003 {published data only}
    1. Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C, Moulin B. Amlodipine reduces cyclosporin‐induced hyperuricaemia in hypertensive renal transplant recipients. Nephrology Dialysis Transplantation 2003;18(10):2147‐53. [MEDLINE: ] - PubMed
Cuharadoglu 1993 {published data only}
    1. Cuharadoglu S, Demirbas S, Haberal M. Results of verapamil treatment in 40 kidney transplant recipients [abstract]. Nephrology Dialysis Transplantation 1993;8:1038. [CENTRAL: CN‐00260880]
Dawidson 1989 {published data only}
    1. Dawidson I, Rooth P, Fry WR, Sandor Z, Wilms C, Coorpender L, et al. Prevention of acute cyclosporine‐induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 1989;48(4):575‐80. [MEDLINE: ] - PubMed
Dawidson 1992 {published data only}
    1. Dawidson I, Lu C, Palmer B, Peters P, Rooth P, Risser R, et al. Verapamil (VP) improves the outcome after renal transplantation. Transplant International 1992;5 Suppl 1:S60‐2. [MEDLINE: ] - PubMed
Donmez 1999 {published data only}
    1. Donmez A, Karaaslan D, Sekerci S, Akpek E, Karakayali H, Arslan G. The effects of diltiazem and dopamine on early graft function in renal transplant recipients. Transplantation Proceedings 1999;31(8):3305‐6. [MEDLINE: ] - PubMed
Duggan 1985 {published data only}
    1. Duggan KA, MacDonald GJ, Charlesworth JA, Pussell BA. Verapamil prevents post‐transplant oliguric renal failure. Clinical Nephrology 1985;24(6):289‐91. [MEDLINE: ] - PubMed
el‐Agroudy 2003 {published data only}
    1. el‐Agroudy AE, Hassan NA, Foda MA, Ismail AM, el‐Sawy EA, Mousa O, et al. Effect of angiotensin II receptor blocker on plasma levels of TGF‐beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. American Journal of Nephrology 2003;23(5):300‐6. [MEDLINE: ] - PubMed
Ferguson 1990 {published data only}
    1. Ferguson CJ, Hillis AN, Williams JD, Griffin PJ, Salaman JR. Calcium‐channel blockers and other factors influencing delayed function in renal allografts. Nephrology Dialysis Transplantation 1990;5(9):816‐20. [MEDLINE: ] - PubMed
Gossmann 2002 {published data only}
    1. Gossmann J, Mondorf U, Dietz A, Kramer W, Kachel HG, Geiger H, et al. A randomized prospective double‐blind placebo‐controlled study of gallopamil, calcium antagonist of the verapamil type, in stable cyclosporine‐treated renal transplant recipients. Transplantation Proceedings 2002;34(5):1767‐70. [MEDLINE: ] - PubMed
Harper 1992 {published data only}
    1. Harper SJ, Moorhouse J, Veitch PS, Horsburgh T, Walls J, Bell PR, et al. Nifedipine improves immediate, and 6‐ and 12‐month graft function in cyclosporin A (CyA) treated renal allograft recipients. Transplant International 1992;5 Suppl 1:S69‐72. [MEDLINE: ] - PubMed
Harper 1996 {published data only}
    1. Harper SJ, Harris K, Jurewicz A, Walls J, Veitch P, Feehally J. Beneficial effects of oral nifedipine on cyclosporin (cya) treated renal allograft recipients ‐ a randomised prospective study [abstract]. XIIIth International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:381. [CENTRAL: CN‐00509226]
    1. Harper SJ, Moorhouse J, Abrams K, Jurewicz A, Nicholson M, Horsburgh T, et al. The beneficial effects of oral nifedipine on cyclosporin‐treated renal transplant recipients ‐ a randomised prospective study. Transplant International 1996;9(2):115‐25. [MEDLINE: ] - PubMed
Kelly 1990 {published data only}
    1. Kelly JJ, Walker RG, D'Apice AJ, Kincaid‐Smith P. A prospective study of the effect of diltiazem in renal allograft recipients receiving cyclosporine A: preliminary results. Transplantation Proceedings 1990;22(5):2127‐8. [MEDLINE: ] - PubMed
Kumana 2003 {published data only}
    1. Kumana CR, Tong MK, Li CS, Lauder IJ, Lee JS, Kou M, et al. Diltiazem co‐treatment in renal transplant patients receiving microemulsion cyclosporin. British Journal of Clinical Pharmacology 2003;56(6):670‐8. [MEDLINE: ] - PMC - PubMed
Lehtonen 2000 {published data only}
    1. Lehtonen S, Isoniemi H, Salmela K. A randomised placebo controlled study on initial isradipine therapy in renal transplantation; long‐term results [abstract]. Nephrology Dialysis Transplantation 2000;15(9):A276. [CENTRAL: CN‐00461150]
Madsen 1998 {published data only}
    1. Madsen JK, Sorensen SS, Hansen HE, Pederson EB. The effect of felodipine on renal function and blood pressure in cyclosporin‐treated renal transplant recipients during the first three months after transplantation. Nephrology Dialysis Transplantation 1998;13(9):2327‐34. [MEDLINE: ] - PubMed
McLaughlin 2005 {published data only}
    1. McLaughlin GE, Abitol CL. Reversal of oliguric tacrolimus nephrotoxicity in children. Nephrology Dialysis Transplantation 2005;20(7):4171‐5. [MEDLINE: ] - PubMed
McNally 1990 {published data only}
    1. McNally PG, Walls J, Feehally J. The effect of nifedipine on renal function in normotensive cyclosporin‐A‐treated renal allograft recipients. Nephrology Dialysis Transplantation 1990;5(11):962‐8. [MEDLINE: ] - PubMed
Midtvedt 1999 {published data only}
    1. Midtvedt K, Hatmann A, Fauchald P, Sund S, Foss A, Nordal KP, et al. Nifedipine slow release reduces the incidence of acute rejections in hypertensive renal transplant recipients [abstract]. Nephrology Dialysis Transplanatation 1999;14(9):A308. [CENTRAL: CN‐00485098]
Midtvedt 2001 {published data only}
    1. Midtveddt K, Hartmaan A, Foss A, Fauchald P, Nordal KP, Rootwelt K, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001;72(11):1787‐92. [MEDLINE: ] - PubMed
    1. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double‐blind study. Transplantation 2001;72(1):107‐11. [MEDLINE: ] - PubMed
    1. Midtvedt kK, Hartmann A, Holdaas A, Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double blind randomised comparative trial. Clinical Transplantation 2001;15(6):426‐31. [MEDLINE: ] - PubMed
Parrott 1990 {published data only}
    1. Parrott NR, Forsythe JL, Mathews JN, Lennard TWJ, Rigg KM, Proud G, et al. Late perfusion. A simple remedy for renal allograft primary nonfunction. Transplantation 1990;49(5):913‐5. [MEDLINE: ] - PubMed
Pedersen 1995 {published data only}
    1. Pedersen EB, Madsen JK, Kornerup HJ, Sorensen SS, Zachariae H. Ciclosporine nephrotoxicity can be counteracted by a calcium antagonist (felodipine) in acute and short‐term studies [abstract]. Journal of the American Society of Nephrology 1995;6(3):1102. [CENTRAL: CN‐00485392]
Pedersen 1996 {published data only}
    1. Pedersen EB, Madsen JK, Sorensen SS, Zachariae H. Improvement in renal function by felodipine during cyclosporine treatment in acute and short‐term studies. Kidney International ‐ Supplement 1996;55:94‐6. [MEDLINE: ] - PubMed
Pirsch 1993 {published data only}
    1. Pirsch JD, D'Alessandro AM, Roecker EB, Knechtle SJ, Reed A, Sollinger HW, et al. A controlled, double‐blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. American Journal of Kidney Diseases 1993;21(2):189‐95. [MEDLINE: ] - PubMed
Po 1994 {published data only}
    1. Po C, Alvez L, Caldwell I, Raja R. Long term effects of calcium channel blockers on proteinuria in renal transplant patients on cyclosporine [abstract]. Journal of the American Society of Nephrology 1994;5(3):1030.
Propper 1989 {published data only}
    1. Propper DJ, Whiting PH, Power DA, Edward N, Catto GR. The effect of nifedipine on graft function in renal allograft recipients treated with cyclosporin A. Clinical Nephrology 1989;32(2):62‐7. [MEDLINE: ] - PubMed
Puig 1991 {published data only}
    1. Puig JM, Lloveras J, Oliveras A, Costa A, Aubia J, Masramon J. Usefulness of diltiazem in reducing the incidence of acute tubular necrosis in Euro‐Collins‐preserved cadaveric renal grafts. Transplantation Proceedings 1991;23(5):2368‐9. [MEDLINE: ] - PubMed
Santos 2002 {published data only}
    1. Santos AF, Keitel E, Bittar A, Neto JP, Alves MD, Schaefer PG, et al. Long term results of diltiazem use associated to cyclosporin in renal transplantation. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (USA). 2002. [CENTRAL: CN‐00416584]
Scheuermann 1995 {published data only}
    1. Scheuermann EH, Gossmann J, Peschke B, Kachel HG, Schoeppe W. A randomized, double blind, placebo controlled study of gallo‐pamil in cyclosporine treated renal transplant recipients [abstract]. Journal of the American Society of Nephrology 1995;6(3):1114. [CN‐00485739]
Schott 1994 {published data only}
    1. Schott G, Prom T. Intraoperative cortical PO2 measurement in kidney transplantation. the effect of the calcium antagonist diltiazem. Urologe 1994;33(5):415‐21. [MEDLINE: ] - PubMed
Sennesael 1996 {published data only}
    1. Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine‐treated renal allograft recipients. American Journal of Kidney Diseases 1996;27(5):701‐8. [MEDLINE: ] - PubMed
Sobh 1989 {published data only}
    1. Sobh MA, Shehab el‐Din AB, Moustafa FE, el‐Far MA, Hussein ME, Gad HM, et al. A prospective randomized study of the protective effect of verapamil on ischemic renal injury in renal allotransplants. Transplantation Proceedings 1989;21(1):1230‐2. [MEDLINE: ] - PubMed
Sonzogni 1995 {published data only}
    1. Sonzogni G, Perico N, Gaspari F, Amuchastegui CS, Ruggenenti P. Effect of calcium‐channel blockade on renal hemodynamics and cyclosporine (csa) pharmacokinetcis in randomized double‐blind dose‐response study in stable renal allograft recipients [abstract]. Journal of the American Society of Nephrology 1995;6(3):1116. [CENTRAL: CN‐00485960]
van Riemsdijk 2000 {published data only}
    1. Riemsdijk IC, Mulder PG, Fijter JW, Bruijn JA, Hooff JP, Hoitsma AJ, et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double‐blind, randomized, placebo‐controlled, multi‐center study. Transplantation 2000;70(1):122‐6. [MEDLINE: ] - PubMed
Venkat 1995 {published data only}
    1. Venkat Raman G, Griffin P, Moore R, Goodship T. Effects of amlodipine on renal function and cyclosporine pharmacokinetics in normotensive renal transplant recipients. XIIIth International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:381.
Wahlberg 1992 {published data only}
    1. Wahlberg J, Hanas E, Bergstrom C, Fellstrom B, Skarp‐Orbeg I, Frodin L. Diltiazem treatment with reduced dose of cyclosporine in renal transplant recipients. Transplantation Proceedings 1992;24(1):311‐2. [MEDLINE: ] - PubMed

References to studies awaiting assessment

Frei 1990 {published data only}
    1. Frei U, Harms A, Bakovic‐Alt R, Pichlmayr R, Koch K. Calcium channel blockers for kidney protection. Journal of Cardiovascular Pharmacology 1990;16 Suppl 6:S11‐5. [MEDLINE: ] - PubMed

Additional references

ANZDATA 2000
    1. Australian and New Zealand Society of Nephrology. Australian and New Zealand Dialysis and Transplant Registry. http://www.anzdata.org.au/anzdata/AnzdataReport/download.htm (accessed May 2000).
Asberg 1997
    1. Asberg A, Christensen H, Hartmann A, Berg KJ. Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin‐1. Clinical Transplantation 1998;12(5):363‐70. [MEDLINE: ] - PubMed
Chien 1980
    1. Chien KR, Sherman SC, Mittnacht S Jr, Farber JL. Microsomal membrane structure and function subsequent to calcium activation of an endogenous phospholipase. Archives of Biochemistry & Biophysics 1980;205(2):614‐22. [MEDLINE: ] - PubMed
Chrysostomou 1993
    1. Chrysostomou A, Walker RG, Russ GR, d'Apice AJ, Knicaid‐Smith P, Mathew TH. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993;55(2):300‐4. [MEDLINE: ] - PubMed
Dickersin 1994
    1. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286‐91. [MEDLINE: ] - PMC - PubMed
Egger 1997
    1. Egger M, Davey‐Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple graphical test. BMJ 1997;315(7109):629‐34. [MEDLINE: ] - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
Lefebvre 1996
    1. Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium; 1996 Oct 20‐24; Adelaide (Australia). 1996.
Mandreoli 1990
    1. Mandreoli M, Esposti ED, Cocchi R, Fabbri A, Guerrini L, Fusaroli M. Do calcium channel blockers have any influence on the immunological status of renal graft recipients on ciclosporin therapy?. American Journal of Nephrology 1990;10(1):58‐60. [MEDLINE: ] - PubMed
Matthys 1984
    1. Matthys E, Patel Y, Kreisberg J, Stewart JH, Venkatachalam M. Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney International 1984;26(2):153‐61. [MEDLINE: ] - PubMed
McCord 1985
    1. McCord JM. Oxygen‐derived free radicals in postischemic tissue injury. New England Journal of Medicine 1985;312(3):159‐63. [MEDLINE: ] - PubMed
McMillen 1985
    1. McMillen MA, Lewis T, Jaffe BM, Wait RB. Verapamil inhibition of lymphocyte proliferation and function in vitro. Journal of Surgical Research 1985;39(1):76‐80. [MEDLINE: ] - PubMed
Morris 1998
    1. Morris RG, Jones TE. Diltiazem disposition and metabolism in recipients of renal transplants. Therapeutic Drug Monitoring 1998;20(4):365‐70. [MEDLINE: ] - PubMed
Nicholson 1996
    1. Nicholson ML, Veitch PS, Bell PR. A prospective randomised study of the effect of nicardipine on ischaemic renal injury in renal allografts. Transplant International 1996;9(1):51‐6. [MEDLINE: ] - PubMed
USRDS 2006
    1. United States Renal Data System. www.usrds.org/atlas.htm (accessed April 2007).
Wilson 1984
    1. Wilson DR, Arnold PE, Burke TJ, Schrier RW. Mitochondrial calcium accumulation and respiration in ischemic acute renal failure in the rat. Kidney International 1984;25(3):519‐26. [MEDLINE: ] - PubMed

References to other published versions of this review

Shilliday 2003
    1. Shilliday I, Woo YM. Calcium antagonists for preventing acute tubular necrosis in renal transplant recipients. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD003421] - DOI
Shilliday 2004
    1. Shilliday IR, Sherif M. Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003421.pub2] - DOI - PubMed
Shilliday 2005
    1. Shilliday IR, Sherif M. Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003421.pub3] - DOI - PubMed

MeSH terms

Substances